Seroprevalence of Poliovirus Antibodies in the United States Population, 2009–2010 by Gregory S. Wallace et al.
RESEARCH ARTICLE Open Access
Seroprevalence of Poliovirus Antibodies in
the United States Population, 2009–2010
Gregory S. Wallace, Aaron T. Curns*, William C. Weldon and M. Steven Oberste
Abstract
Background: Polio is eliminated in the United States, with the last indigenous transmission occurring in 1979.
However, global eradication of polio has not yet been completed, so importation of poliovirus into the U.S. is still
possible. Specimens from the 2009-10 National Health and Nutrition Examination Survey (NHANES) were analyzed
to evaluate population seroprevalence and assess overall risk from a poliovirus importation.
Methods: We evaluated prevalence of serum antibodies to all three poliovirus types using the National Health and
Nutrition Examination Survey during 2009–2010.
Results: The overall seroprevalence to poliovirus was 93.9 % for type 1, 97.0 % for type 2, and 83.1 % for type 3.
Seroprevalence was higher for type 2 compared to the other types (p < 0.001) and lower for type 3 compared to
the other types (p < 0.001). There was a tendency for higher seroprevalence in the younger age groups, but this
varied by serotype.
Conclusions: Seroprevalence was high (83.1 %–97.0 %) for all three types of poliovirus in the US population during
2009–2010. While there were observed differences by serotype with type 2 having the highest seroprevalence and
type 3 having the lowest, consistent with previous observations, no large immunity gaps to poliovirus suggesting
an imminent substantial population risk from a poliovirus importation were observed at a population level.
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Background
Pakistan and Afghanistan remain the only two countries
where wild poliovirus (WPV) transmission has never
been interrupted [1–3]. While the last cases of indigen-
ously acquired WPV in the United States (U.S.) occurred
in 1979, the last WPV case in a U.S. resident traveling
abroad occurred in 1986, and the last WPV imported
case occurred in 1993. Due to continued WPV transmis-
sion in a few remaining areas of the world, CDC has
provided interim vaccination guidance for travel to and
from countries affected by wild poliovirus [4].
Additionally, circulating vaccine-derived poliovirus
(cVDPV) must also be eliminated before polio eradica-
tion is achieved [5]. Since 2000, the United States has
exclusively used inactivated poliovirus vaccine (IPV), in
order to prevent vaccine-associated paralytic poliovirus
cases (VAPP) which averaged 8–10 cases per year in the
U.S. when oral poliovirus vaccine (OPV) was routinely
recommended [6]. No systematic serosurveys for polio-
virus antibodies have been conducted in the U.S. since
the return to an all-IPV recommendation [7, 8]. This
study describes the findings of a serosurvey conducted
using the 2009-10 National Health and Nutrition Exam-
ination Survey (NHANES).
Methods
NHANES is conducted by the National Center for
Health Statistics (NCHS), Centers for Disease Control
and Prevention (CDC), to assess the health and
nutritional status of the US population [9]. The survey
uses a stratified, multistage, probability-cluster design, to
provide a sample representative of the civilian non-
institutionalized US population. Survey participants
undergo household interviews and standardized physical
examinations, and provide biological samples for testing.
Non-Hispanic blacks and Hispanics were over-sampled
to provide stable estimates for these groups. Informed
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consent was obtained from all participants, and the
Institutional Review Board of NCHS, CDC approved the
protocol.
Seroprevalence for antibodies against poliovirus sero-
types 1-3 was compared by demographic characteristics
for 4806 individuals aged 6 to 49 years who participated in
the 2009–2010 NHANES. The NHANES sample is
designed to provide population-based estimates that are
nationally representative of the US population [10]. Sero-
prevalence was compared by gender, age group (6–11,
12–19, 20–39, and 40–49 years), race/ethnicity (Mexican-
American, Other Hispanic, Non-Hispanic White, Non-
Hispanic Black, Other Race – Including Multi-Racial),
and country of birth (United States or Other).
The data were analyzed using SUDAAN 11.0 (Research
Triangle Institute, Research Triangle Park, NC) and SAS
9.3 (SAS Institute, Cary NC). t-tests were used to evaluate
differences in seroprevalence by demographic characteris-
tics and serotype. P-values <0.05 were considered statisti-
cally significant and were not adjusted for multiple
comparisons. All statistical analyses and 95 % Clopper-
Pearson confidence intervals for the seroprevalence point
estimates accounted for the NHANES complex survey
design [10].
Serum samples from NHANES participants aged 6–49
years during 2009–2010 were tested for poliovirus-
specific antibodies. Samples were tested using a standard
microneutralization assay for antibodies to poliovirus
types 1, 2, and 3, according to established protocols at
the Global Polio Specialized Laboratory, Centers for Dis-
ease Control and Prevention (CDC) [11]. Briefly, 80-100
CCID50 (50 % cell culture infectious dose) of each polio-
virus serotype and two-fold serial dilutions of serum
were separately combined and pre-incubated at 35 °C
for 3 h before addition of HEp-2(C) cells (human cervix
carcinoma cell line). After incubation for 5 days at 35 °C
and 5 % CO2, plates were stained with crystal violet and
cell viability measured by optical density in a plate spec-
trophotometer. Each specimen was run in triplicate, with
parallel specimens from one study subject tested in the
same assay run, and the neutralization titers estimated
by the Spearman-Kärber method [12] and reported as
the reciprocal of the calculated 50 % endpoint. Each run
contained multiple replicates of a reference antiserum
pool to monitor performance variation. A serum sample




Of 6981 persons aged 6–49 years sampled for NHANES
2009–2010, 5785 (83 %) were interviewed and 5652
(81 %) were examined. Of those examined, 4806 (85 %)
had serum samples available for poliovirus antibody
testing. The proportion of examined participants with
tested samples varied by age (6–11 years, 74 %; 12–19
years, 85 %; 20–39 years, 89 %; 40–49 years, 91 %; p <
0.001), race/Hispanic origin (Mexican American, 91 %;
Other Hispanic, 76 %; non-Hispanic white, 85 %; non-
Hispanic black, 82 %; non-Hispanic Other/Multi-racial,
88 %; p < 0.001), and birthplace (US, 84 %; non-US, 87 %;
p < 0.05), but not by gender.
Overall seroprevalence of poliovirus antibody for types 1,
2, and 3
During 2009–2010, among the US population aged 6–49
years, overall poliovirus seroprevalence for types 1, 2,
and 3 was 93.9 % (95 % CI: 92.5 %–95.0 %), 97.0 %
(95 % CI: 95.9 %–97.9 %) and 83.1 % (95 % CI: 80.7 %–
85.4 %), respectively. Seroprevalence was higher for type
2 compared to type 1 and type 3 (p < 0.001 for each
comparison) and seroprevalence for type 1 was also
higher than type 3 (p <0.001). Less than 1 % of those
tested were negative to all 3 serotypes.
Seroprevalence of poliovirus type 1 antibody
Poliovirus seroprevalence did not differ by gender but was
higher among those aged 6–11 years compared to those
aged 20–39 and 40–49 years (p < 0.05 for each compari-
son, Table 1, Fig. 1). When stratified by gender, those aged
6–11 years had a higher seroprevalence than those aged
20–39 for both males and females (p < 0.05 and p < 0.001,
respectively). No other differences between other age
groups were observed for either gender. Within each age
group and overall, no differences by gender were ob-
served. The U.S. born group had poliovirus seroprevalence
levels higher than the non-U.S. born group (p < 0.05).
Non-Hispanic Blacks had higher seroprevalence com-
pared to Mexican-Americans and Other Hispanics (p <
0.05 for each comparison). When stratified by age, no
differences were observed by race/ethnicity within the
6–11 or 12–19 year age group (Fig. 2). Within the 20–
39 year age group, Non-Hispanic Blacks had a higher
seroprevalence than Other Hispanics (p < 0.05). Within
the 40–49 year age group, Non-Hispanic Blacks had a
higher seroprevalence than Mexican-Americans and
Non-Hispanic Whites had a higher seroprevalence than
Mexican-Americans and Other Hispanics (p < 0.05).
Among Mexican-Americans, those aged 6–11 years had
a higher seroprevalence than those aged 12–19, 20–39,
and 40–49 years (p < 0.05, p < 0.05, and p < 0.001, respect-
ively). Those aged 12–19 years had a higher seropreva-
lence than those aged 40–49 years (p < 0.05).
Similarly, among Other Hispanics, those aged 6–11
years had a higher seroprevalence than those aged 20–39
and 40–49 years (p < 0.05 for each comparison), and those
aged 12–19 years had a higher seroprevalence than those
aged 40–49 years (p < 0.05).
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Table 1 Seroprevalence in the United States to Poliovirus by Serotype and Demographics
Poliovirus Serotype 1 Poliovirus Serotype 2 Poliovirus Serotype 3
Percent positive
(+/- 95 % Confidence Interval)
Percent positive
(+/- 95 % Confidence Interval)
Percent positive
(+/- 95 % Confidence Interval)
Gender
Female 93.4 (91.7–94.9) 97.3 (96.1–98.2) 83.5 (80.4–86.4)
Male 94.3 (92.4–95.8) 96.6 (95.1–97.8) 82.7 (80.4–84.9)
Age Group (yrs)
6–11 97.2 (94.7–98.8) 98.0 (96.4–99.0) 93.8 (91.8–95.4)
12–19 94.7 (92.0–96.6) 98.2 (96.6–99.2) 84.3 (81.0–87.2)
20–39 92.7 (90.0–94.2) 96.9 (95.2–98.2) 78.6 (74.6–82.2)
40–49 93.9 (91.6–95.7) 95.8 (93.8–97.3) 85.8 (82.3–88.8)
Gender and Age
Female
6–11 97.5 (94.8–99.0) 98.8 (96.3–99.8) 93.6 (90.5–95.9)
12–19 94.7 (90.7–97.3) 98.4 (96.6–99.4) 82.8 (78.0–86.2)
20–39 91.9 (89.5–93.9) 97.0 (94.3–98.7) 78.6 (73.9–82.9)
40–49 93.6 (89.9–96.3) 96.6 (94.3–98.1) 88.5 (84.6–91.7)
Male
6–11 97.0 (92.6–99.2) 97.2 (94.8–98.7) 94.0 (91.2–96.1)
12–19 94.7 (90.0–97.6) 98.0 (95.7–99.3) 85.8 (80.6–90.0)
20–39 93.5 (91.0–95.5) 96.8 (95.4–97.9) 78.6 (74.1–82.6)
40–49 94.1 (91.5–96.1) 95.0 (91.4–97.4) 82.9 (78.4–86.8)
Race/Ethnicity
Mexican-American 92.4 (89.6–94.6) 94.3 (92.4–95.9) 80.3 (77.0–82.5)
Other Hispanic 90.1 (84.5–94.2) 94.9 (91.3–97.4) 83.2 (78.6–87.2)
Non-Hispanic White 94.5 (92.6–96.0) 97.3 (95.9–98.3) 83.6 (80.9–86.0)
Non-Hispanic Black 95.0 (93.0–96.6) 98.4 (97.3–99.2) 85.2 (80.8–89.0)
Non-Hispanic Other 92.5 (86.8–96.2) 98.1 (94.8–99.6) 81.3 (70.8–89.2)
Age & Race/Ethnicity
6–11
Mexican-American 98.5 (96.4–99.5) 98.2 (96.0–99.4) 97.7 (94.7–99.3)
Other Hispanic 98.8 (93.5–100.0) 99.2 (94.7–100.0) 93.8 (87.0–97.7)
Non-Hispanic White 96.9 (93.1–98.9) 97.6 (94.9–99.1) 92.3 (88.5–95.2)
Non-Hispanic Black 99.1 (96.0–99.9) 99.1 (96.3–99.9) 96.1 (90.6–98.8)
Non-Hispanic Other 92.8 (83.1–97.9) 97.6 (87.6–99.9) 91.1 (81.0–96.9)
12–19
Mexican-American 93.7 (90.5–96.1) 98.4 (96.3–99.4) 80.4 (74.5–85.4)
Other Hispanic 96.1 (90.2–98.9) 99.1 (94.7–100.0) 88.5 (81.0–93.8)
Non-Hispanic White 94.7 (89.5–97.8) 97.7 (95.1–99.2) 84.3 (79.3–88.5)
Non-Hispanic Black 93.8 (89.4–96.7) 99.6 (97.7–100.0) 84.6 (79.3–89.0)
Non-Hispanic Other 97.1 (90.7–99.6) 98.6 (93.0–100.0) 88.5 (79.3–94.6)
20–39
Mexican-American 91.2 (86.1–94.9) 93.7 (90.2–96.2) 76.2 (71.5–80.4)
Other Hispanic 86.7 (78.5–92.6) 94.2 (89.8–97.1) 78.4 (70.5–84.9)
Non-Hispanic White 93.6 (91.2–95.5) 97.2 (95.3–98.5) 79.2 (75.1–82.9)
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Among Non-Hispanic Whites, those aged 6–11 years
had a higher seroprevalence than those aged 20–39 years
(p < 0.05). Among Non-Hispanic Blacks, those aged 6–11
years had a higher seroprevalence than those aged 12–19,
20–39, and 40–49 years (p < 0.05 for each comparison).
No statistically significant differences were observed by
age group within Non-Hispanic Others.
Seroprevalence of poliovirus type 2 antibody
Poliovirus seroprevalence did not differ by gender but was
higher among those aged 6–11 years compared to those
aged 40–49 years (p < 0.05, Table 1, Fig. 1). Those aged
12–19 years had a higher seroprevalence than those aged
40–49 years (p < 0.05). When stratified by gender, those
aged 6–11 years had a higher seroprevalence than those
aged 40–49 years for females (p < 0.05) and those aged
12–19 years had a higher seroprevalence than those aged
40–49 years for males (p < 0.05). No other differences be-
tween other age groups were observed for either gender.
Within each age group, no differences by gender were ob-
served. The U.S. born group had poliovirus seroprevalence
levels higher than the non-U.S. born group (p < 0.05).
Table 1 Seroprevalence in the United States to Poliovirus by Serotype and Demographics (Continued)
Non-Hispanic Black 94.7 (91.5–96.9) 98.4 (96.4–99.5) 81.6 (75.8–86.6)
Non-Hispanic Other 90.5 (82.4–95.8) 98.9 (92.4–100.0) 74.3 (54.9–88.6)
40–49
Mexican-American 89.1 (83.9–93.1) 88.7 (80.9–94.1) 75.8 (69.5–81.3)
Other Hispanic 89.4 81.6–94.7) 91.3 (82.4–96.7) 85.4 (72.5–93.8)
Non-Hispanic White 94.9 (91.7–97.1) 97.0 (94.3–98.6) 87.0 (82.1–91.0)
Non-Hispanic Black 94.7 (90.0–97.6) 96.9 (92.1–99.2) 87.3 (78.7–93.8)
Non-Hispanic Other 92.9 (75.0–99.2) 96.1 (87.2–99.5) 86.2 (68.9–95.9)
U.S. Born
Yes 94.5 (93.2–95.6) 97.5 (96.3–98.4) 83.9 (81.6–86.1)
No 90.8 (87.4–93.6) 94.6 (92.7–96.1) 79.4 (72.9–84.9)
Total 93.9 (92.5–95.0) 97.0 (95.9–97.9) 83.1 (80.7–85.4)
Fig. 1 Seroprevalence of Poliovirus Antibodies by Birth Cohort
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Non-Hispanic Blacks had higher seroprevalence com-
pared to Mexican-Americans and Other Hispanics (p <
0.001, p < 0.05, respectively). Non-Hispanic Whites and
Non-Hispanic Other also had a higher seroprevalence than
Mexican-Americans (p < 0.05 for each comparison). When
stratified by age, no differences were observed by race/eth-
nicity within the 6–11 or 12–19 year age group (Fig. 3).
Within the 20–39 year age group, Non-Hispanic Blacks,
Non-Hispanic Whites, and Non-Hispanic Other had a
higher seroprevalence than Mexican-Americans (p < 0.05,
p < 0.05 and p < 0.001, respectively). Non-Hispanic Blacks
and Non-Hispanic Other had a higher seroprevalence than
Other Hispanic (p < 0.05 for each comparison). Within
the 40–49 year age group, Non-Hispanic Blacks and
Non-Hispanic Whites had a higher seroprevalence than
Mexican-Americans (p < 0.05 for each comparison).
Among Mexican-Americans, those aged 6–11 years
had a higher seroprevalence than those aged 20–39 and
40–49 years (p < 0.05 for each comparison). Those aged
12–19 years had a higher seroprevalence than those aged
20–39 and 40–49 years (p < 0.05 for each comparison).
Among Other Hispanics, those aged 6–11 years had a
higher seroprevalence than those aged 20–39 and 40–49
years (p < 0.05 for each comparison). Those aged 12–19
years had a higher seroprevalence than those aged 20–39
and 40–49 years (p < 0.05 for each comparison).
No statistically significant differences were observed by
age group among Non-Hispanic Blacks, Non-Hispanic
Whites, or Non-Hispanic Others.
Seroprevalence of poliovirus type 3 antibody
Poliovirus seroprevalence did not differ by gender but
was higher among those aged 6–11 years compared to
those aged 12–19, 20–39 and 40–49 years (p < 0.001 for
each comparison, Table 1, Fig.1). Those aged 12–19 and
40–49 years had a higher seroprevalence than those aged
20–39 years (p < 0.05 and p < 0.001, respectively). When
stratified by gender, those aged 6–11 years had a higher
seroprevalence than those aged 12–19, 20–39, and 40–49
for both males and females (p < 0.05, p < 0.001, and p <
0.001, respectively for males and p < 0.001, p < 0.001, and
p < 0.05, respectively for females). Those aged 40–49 years
had a higher seroprevalence than those aged 12–19 and
20–39 years for females (p < 0.05 and p < 0.001, respect-
ively) and those aged 12–19 years had a higher seropreve-
lance than those aged 20–39 years for males (p < 0.05).
Among those aged 40–49 years, males had a higher sero-
prevalence than females (p < 0.05). Within the other age
groups, no differences by gender were observed. No sig-
nificant difference in seroprevalence was observed be-
tween U.S. born group and non-U.S. born group.
Non-Hispanic Blacks and Non-Hispanic Whites had
higher seroprevalence compared to Mexican-Americans
(p < 0.05 for each comparison). When stratified by age, for
those aged 6–11 years, Mexican-Americans had a higher
seroprevelance than Non-Hispanic Whites and Non-
Hispanic Other (p < 0.05 for each comparison, Fig. 4).
Within the 12–19 year age group, Other Hispanics had a
higher seroprevalence than Mexican-Americans (p < 0.05).
Fig. 2 Seroprevalence of Poliovirus Antibodies by Birth Cohort & Race/Ethnicity for Serotype 1
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Fig. 3 Seroprevalence of Poliovirus Antibodies by Birth Cohort & Race/Ethnicity for Serotype 2
Fig. 4 Seroprevalence of Poliovirus Antibodies by Birth Cohort & Race/Ethnicity for Serotype 3
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Within the 20–39 year age group, Non-Hispanic Blacks
had a higher seroprevalence than Mexican-Americans
(p < 0.05). Within the 40–49 year age group, Non-
Hispanic Blacks, Non-Hispanic Whites, and Other
Hispanics had a higher seroprevalence than Mexican
Americans (p < 0.05 for each comparison).
Among Mexican-Americans, those aged 6–11 years had
a higher seroprevalence than those aged 12–19, 20–39,
and 40–49 years (p < 0.001 for each comparison). Among
Other Hispanics, those aged 6–11 years had a higher sero-
prevalence than those aged 20–39 years (p < 0.001) and
those age 12–19 years had a higher seroprevalence than
those aged 20–39 years (p < 0.05). Among Non-Hispanic
Whites, those aged 6–11 years had a higher seropreva-
lence than those aged 12–19, 20–39, and 40–49 years
(p < 0.05, p < 0.001, and p < 0.05, respectively) and those
age 40–49 years had a higher seroprevalence than those
aged 20–39 years (p < 0.05). Among Non-Hispanic Blacks,
those aged 6–11 years had a higher seroprevalence than
those aged 12–19, 20–39, and 40–49 years (p < 0.001, p <
0.001, and p < 0.05, respectively). Among Non-Hispanic
Other, those age 12–19 years had a higher seroprevalence
than those aged 20–39 years (p < 0.05).
Comparison of antibody seroprevalence between the
three poliovirus serotypes
Seroprevalence for serotype 1 was higher than serotype
3 for all four age groups: 6–11, 12–19, 20–39, and 40–
49 years (p < 0.05, p < 0.001, p < 0.001, and p < 0.001, re-
spectively, Fig. 1) as well as for each gender (p < 0.05 for
each comparison). Seroprevalence for serotype 2 was
also higher than serotype 3 for all four age groups (p <
0.001 for all age groups) as well as for each gender (p <
0.001 for each comparison). Seroprevalence for serotype
2 was greater than serotype 1 for those aged 12–19 years
and 20–39 years (p < 0.001 for both age groups). Sero-
prevalence for serotype 2 was greater than serotype 1
among both females and males (p < 0.001 and p < 0.05,
respectively).
Seroprevalence for serotype 1 was higher than serotype 3
for all race/ethnicity groups: Mexican-American, Other
Hispanic, Non-Hispanic Whites, Non-Hispanic Blacks, and
Non-Hispanic Other (p < 0.001, p < 0.05, p < 0.001, p <
0.001, and p < 0.05, respectively). Seroprevalence for sero-
type 2 was also higher than serotype 3 for all race/ethnicity
groups (p < 0.001 for groups other than Non-Hispanic
Other [p < 0.05]). Seroprevalence for serotype 2 was greater
than serotype 1 for Other Hispanic, Non-Hispanic Whites,
Non-Hispanic Blacks, and Non-Hispanic Other (p < 0.05,
p < 0.001, p < 0.001, and p < 0.05, respectively).
Discussion
Overall seroprevalence for antibodies against poliovirus
serotypes 1-3 was high in the US population aged 6–49
years during 2009–2010. Seroprevalence was highest
among those aged 6–11 years, a group likely to have re-
cently completed a full poliovirus vaccine schedule. A
general trend of lower seroprevalence with increasing
age was observed; however, differences for each age
group varied by serotype. Of note, seroprevalence for
serotype 3 was higher for those aged 40–49 years com-
pared to ages 20–39 and 12–19, which is an unexpected
result. It is not clear what led to this finding; it may re-
flect exposure to WPV serotype 3 in a proportion of this
age group during childhood, but this is not known. U.S.
born persons had higher seroprevalence than non-U.S.
born persons for serotypes 1 and 2. Differences by race/
ethnicity varied by age and serotype, and while there was
a tendency for higher seroprevalence rates among non-
Hispanic Blacks and Whites, this was not a universal
finding. Lower seroprevalence among some subgroups
may indicate certain subpopulations may be at increased
risk for transmission and outbreaks if poliovirus was in-
troduced; however, the seroprevalances among all sub-
groups evaluated were near or above the expected crude
herd immunity threshold in a developed country, which
has been estimated at a range of 80–86 % [13]. Never-
theless, given that overall seronegative rates were 6.1 %,
3.0 %, and 16.9 % for serotypes 1, 2, and 3, respectively,
there remains some low level of susceptibility. As long
as poliovirus circulation continues anywhere in the
world, importations remain a risk and consequently,
there remains a limited risk of possible outbreaks among
unvaccinated subpopulations.
This study has some limitations. The analyses relied
on data from NHANES 2009-10 and it is unknown if
these results are generalizable to the current status of
poliovirus immunity in the US. It may be that some of
the differences observed are no longer present as the co-
hort of children and adolescents move into older age
groups. In addition, NHANES did not collect poliovirus
disease or vaccination history so we were unable to dis-
tinguish between immunity due to infection versus vac-
cination. Among US-born persons, natural infection
would be expected to be very rare since circulation of
WPV has been at an extremely low level (or zero) in the
US during the lifetime of all but the oldest of study sub-
jects. Acquisition of infection by a US-born person while
traveling abroad is a possibility, but is also likely to be
relatively rare. Finally, the proportion of individuals that
were surveyed and ultimately tested varied by age group,
race/ethnicity, and U.S. birth status and NHANES can-
not identify small potentially susceptible subpopulations
with precision.
Conclusions
Results from NHANES 2009–2010 indicate high seropreva-
lence to poliovirus in the civilian non-institutionalized U.S.
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population aged 6–49 years and provides evidence to
support prevention of sustained disease transmission
in the U.S. in case of an importation. WPV remains
endemic in only 2 countries, limiting the risk of im-
portation to the U.S., but not eliminating it. Monitor-
ing seroprevalence is an important component of
understanding risks for polio in the U.S. Continued
high vaccine coverage remains paramount in the near
future while the world completes the global elimin-
ation of polio.
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